2025 United States Biosimilar Contract Manufacturing Market Revenue Opportunities Report
Description
The 2025 United States Biosimilar Contract Manufacturing Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Biosimilar Contract Manufacturing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the biosimilar contract manufacturing market in the United States are Boehringer Ingelheim Biopharmaceuticals GmbH, Lonza Group AG, Catalent, Inc., and Biocon. These companies are key players due to their extensive capabilities ranging from process development to commercial-scale manufacturing, complying with stringent FDA regulatory standards. Boehringer Ingelheim, for example, has partnered with Quallent Pharmaceuticals to increase access to biosimilars such as adalimumab-adbm in the U.S., boosting biosimilar adoption and affordability. Lonza and Catalent are known for providing scalable manufacturing solutions using advanced bioprocessing technologies, supporting biopharma companies with flexible, quality-driven contract manufacturing services. Biocon's involvement enhances the market through its strategic manufacturing capacity and global outreach.
The U.S. biosimilar contract manufacturing market is growing rapidly owing to factors like patent expirations of blockbuster biologics, supportive FDA policies, and a rising prevalence of chronic diseases necessitating biosimilars. North America holds the largest market share (~40%) in biosimilar contract manufacturing, driven by extensive healthcare investments and innovation infrastructure. These companies facilitate efficient commercialization of biosimilars by enabling small and mid-sized biotech firms to outsource production, managing regulatory-compliant manufacturing processes. The U.S. market growth also benefits from collaborations, increased R&D investment, and technological advances such as single-use systems and continuous manufacturing processes, which reduce time-to-market and production costs.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Biosimilar Contract Manufacturing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the biosimilar contract manufacturing market in the United States are Boehringer Ingelheim Biopharmaceuticals GmbH, Lonza Group AG, Catalent, Inc., and Biocon. These companies are key players due to their extensive capabilities ranging from process development to commercial-scale manufacturing, complying with stringent FDA regulatory standards. Boehringer Ingelheim, for example, has partnered with Quallent Pharmaceuticals to increase access to biosimilars such as adalimumab-adbm in the U.S., boosting biosimilar adoption and affordability. Lonza and Catalent are known for providing scalable manufacturing solutions using advanced bioprocessing technologies, supporting biopharma companies with flexible, quality-driven contract manufacturing services. Biocon's involvement enhances the market through its strategic manufacturing capacity and global outreach.
The U.S. biosimilar contract manufacturing market is growing rapidly owing to factors like patent expirations of blockbuster biologics, supportive FDA policies, and a rising prevalence of chronic diseases necessitating biosimilars. North America holds the largest market share (~40%) in biosimilar contract manufacturing, driven by extensive healthcare investments and innovation infrastructure. These companies facilitate efficient commercialization of biosimilars by enabling small and mid-sized biotech firms to outsource production, managing regulatory-compliant manufacturing processes. The U.S. market growth also benefits from collaborations, increased R&D investment, and technological advances such as single-use systems and continuous manufacturing processes, which reduce time-to-market and production costs.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
